How GHK-Cu Affects Ferritin

GHK-Cu is glycyl-L-histidyl-L-lysine coordinated to a Cu(II) ion. Elemental copper accounts for ~15.8% of the complex by mass (Cu atomic weight 63.55 / GHK-Cu molecular weight ~401.9 g/mol). A standard 2 mg GHK-Cu injection delivers ~316 mcg of elemental copper subcutaneously, bypassing intestinal regulation entirely.

Copper-iron crosstalk:

• Copper and iron share several transport and storage proteins. Hephaestin, the ferroxidase that loads iron onto transferrin for systemic distribution, is a copper-dependent enzyme. Copper deficiency causes an iron-deficiency-like anaemia despite adequate iron stores.
• Conversely, sustained copper excess can interfere with iron mobilisation by saturating ferroxidase activity and altering hepcidin signalling. The direction of this effect at injectable GHK-Cu doses has not been characterised in humans.
• Ceruloplasmin (the main copper carrier in serum) also has ferroxidase activity and participates in iron-copper crosstalk at the hepatic and reticuloendothelial level.

Ferritin as a marker has two faces:

• Iron storage: ferritin reflects total body iron stores under normal conditions.
• Acute-phase reactant: ferritin rises with systemic inflammation independent of iron status (CRP-correlated).
• If GHK-Cu lowers systemic inflammation (theoretical, based on copper's role in superoxide dismutase and the Pickart gene-expression data, Pickart & Margolina 2018, PMID 29986520), ferritin trends down for non-iron reasons.
• If chronic injected copper drives subclinical inflammation or oxidative stress, ferritin trends up.
• If copper accumulation interferes with iron trafficking, ferritin may drop without true iron deficiency.

The net direction in any individual GHK-Cu user is not predictable from current evidence. No published study has measured ferritin response to chronic injectable GHK-Cu in humans.

Short cycles (4 weeks daily at 2 mg):

• Cumulative copper load ~8.8 mg. Below the oral Tolerable Upper Intake (10 mg/day) but bypassing the gut.
• Ferritin change at this duration is likely within assay noise (typical CV 5-10%).
• Most users will not see a clinically meaningful shift.

Standard cycles (8 weeks daily at 2 mg):

• Cumulative copper load ~17.7 mg.
• Ferritin shifts of 10-30% in either direction are plausible. Direction depends on whether the dominant effect is inflammation modulation (down), iron trafficking interference (down), or acute-phase induction (up).
• The change is not predictable; it must be measured.

Extended cycles (12+ weeks daily at 2 mg):

• Cumulative copper load ~26.6 mg or more.
• Larger ferritin shifts are possible. Pair with serum copper and ceruloplasmin to interpret.
• If ferritin drops while serum copper rises, suspect copper-iron antagonism. If ferritin and CRP both rise, suspect inflammation.

Co-administered AAS: testosterone and nandrolone suppress hepcidin, which lowers ferritin independently of GHK-Cu. On a stacked protocol, ferritin trends are usually dominated by AAS effects on iron handling, not by the peptide.

Baseline (before starting GHK-Cu): full iron panel and copper panel.

• Iron panel: ferritin, serum iron, total iron binding capacity (TIBC), transferrin saturation.
• Copper panel: serum copper (reference 70-140 mcg/dL), ceruloplasmin (reference 20-35 mg/dL), and calculated free copper (serum Cu minus ceruloplasmin times 3, normal 5-15 mcg/dL, Walshe formula).

Week 4: repeat both panels. Triggers:

• Ferritin drop greater than 50%: rule out inflammation masking (check CRP), then investigate iron status (low transferrin saturation confirms true iron depletion).
• Ferritin rise more than 50%: check CRP. If CRP is also up, ferritin elevation is inflammatory. If CRP is normal, consider increased iron stores or copper-related ferritin trafficking changes.
• Serum copper above 140 mcg/dL: hold GHK-Cu and recheck in 4 weeks.

Week 12 (cycle end): full panels again. This is your cycle readout.

Calculated free copper above 15 mcg/dL warrants stopping GHK-Cu. Duncan et al., 2017 PMID 27742851 showed substantial interlaboratory variability in the free copper calculation, particularly when ceruloplasmin is measured immunologically. If free copper is negative or implausible, ask for ceruloplasmin by enzymatic assay or get a 24-hour urinary copper instead.

If ferritin drifts without clear cause:

• Run the full iron panel (serum iron, TIBC, transferrin saturation). True iron deficiency shows low transferrin saturation (under 20%). Inflammatory ferritin elevation shows normal or high transferrin saturation with elevated CRP.
• Run the copper panel in parallel. If serum copper is rising and ferritin is falling, the iron-copper crosstalk explanation is plausible.
• Do not chase ferritin with iron supplementation if the picture is unclear. Iron supplementation in the presence of copper excess can worsen oxidative stress.

If ferritin rises with elevated CRP:

• Investigate non-peptide causes first: training intensity spikes, recent infection, AAS dose changes, alcohol.
• If CRP and ferritin both stay elevated for two consecutive checks without obvious cause, consider pausing GHK-Cu for 4 weeks and rechecking. A return to baseline supports the peptide as a contributor.

For women on GHK-Cu: menstrual iron loss adds variability to ferritin. Time blood draws to the same point in the cycle for serial comparisons, or run the full iron panel rather than ferritin alone.

Do not extrapolate from oral copper supplementation safety data. Oral copper is regulated by the intestine. Injected copper is not. The cumulative load math matters more for the injected route.